Natasha A. Hernday's most recent trade in Janux Therapeutics Inc was a trade of 11,667 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Janux Therapeutics Inc | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 11,667 | 11,667 | - | - | Stock Option (right to buy) | |
| Janux Therapeutics Inc | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 3,750 | 8,731 | - | 0 | Common Stock | |
| XOMA Corp | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 5,971 | 9,006 (0%) | 0% | 0 | Common Stock | |
| Janux Therapeutics Inc | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2024 | 16,700 | 16,700 | - | - | Stock Option (Right to Buy) | |
| Janux Therapeutics Inc | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2024 | 8,350 | 8,350 | - | - | Stock Option (Right to Buy) | |
| Janux Therapeutics Inc | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2024 | 5,000 | 5,000 | - | 0 | Common Stock | |
| Janux Therapeutics Inc | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2024 | 4,111 | 4,111 | - | - | Stock Option (Right to Buy) | |
| Janux Therapeutics Inc | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2024 | 2,500 | 7,500 | - | 0 | Common Stock | |
| Janux Therapeutics Inc | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2024 | 1,231 | 6,231 | - | 0 | Common Stock | |
| Alpine Immune Sciences Inc | Natasha A. Hernday | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 May 2024 | 17,500 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Natasha A. Hernday | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 May 2024 | 15,000 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Natasha A. Hernday | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 May 2024 | 10,000 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Natasha A. Hernday | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 May 2024 | 10,000 | 0 | - | - | Stock Option (Right to buy) | |
| Alpine Immune Sciences Inc | Natasha A. Hernday | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 May 2024 | 7,650 | 0 | - | - | Stock Option (Right to buy) | |
| XOMA Corp | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 4,881 | 4,881 | - | - | Non-Qualified Share Option (right to buy) | |
| XOMA Corp | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 3,035 | 3,035 (0%) | 0% | 0 | Common Stock | |
| Alpine Immune Sciences Inc | A. Hernday Natasha | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 17,500 | 17,500 | - | - | Stock Option (Right to buy) | |
| XOMA Corp | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 10,967 | 10,967 | - | - | Non-Qualified Share Option (right to buy) | |
| Alpine Immune Sciences Inc | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to buy) | |
| XOMA Corp | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 8,996 | 8,996 | - | - | Non-Qualified Share Option (right to buy) | |
| Alpine Immune Sciences Inc | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to buy) | |
| XOMA Corp | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 5,101 | 5,101 | - | - | Non-Qualified Share Option (right to buy) | |
| Alpine Immune Sciences Inc | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 7,650 | 7,650 | - | - | Stock Option (Right to buy) | |
| XOMA Corp | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 25.00 per share. | 15 Dec 2020 | 4,000 | 4,000 | - | 25 | 100,000 | 8.625% Series A Cumulative Perpetual Preferred Stock |
| Alpine Immune Sciences Inc | Natasha A. Hernday | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) |